Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$9.33 USD

9.33
3,135,739

+0.29 (3.21%)

Updated May 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe

by Zacks Equity Research

Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.

ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates

by Zacks Equity Research

ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Why Amicus (FOLD) Might Surprise This Earnings Season

by Zacks Equity Research

Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss

by Zacks Equity Research

Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well

by Zacks Equity Research

Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

Bears are Losing Control Over Amicus Therapeutics (FOLD), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Amicus Therapeutics (FOLD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Stock Jumps 6.4%: Will It Continue to Soar?

by Zacks Equity Research

Amicus Therapeutics (FOLD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amicus (FOLD) Filings for AT-GAA in Pompe Disease Accepted by EMA

by Zacks Equity Research

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss

by Zacks Equity Research

Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.

Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.

Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates

by Zacks Equity Research

Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -5.56% and -2.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View

by Zacks Equity Research

Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.

Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.

Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View

by Zacks Equity Research

Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.